193 related articles for article (PubMed ID: 15940287)
1. Case study: management of advanced prostate cancer with soft tissue metastases.
Kirby R
Prostate Cancer Prostatic Dis; 2005; 8(3):290-2. PubMed ID: 15940287
[No Abstract] [Full Text] [Related]
2. Case study: management of lymph node-positive disease detected at radical prostatectomy.
Kirby R
Prostate Cancer Prostatic Dis; 2005; 8(3):287-9. PubMed ID: 15940288
[No Abstract] [Full Text] [Related]
3. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
4. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
5. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
6. Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy.
Gaur S; Aish LS; Oo TH
J Clin Oncol; 2004 Mar; 22(5):957-8. PubMed ID: 14990654
[No Abstract] [Full Text] [Related]
7. Prostate cancer tissue is masked by bicalutamide: a case report.
Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC
Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193
[TBL] [Abstract][Full Text] [Related]
8. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
9. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
10. Treatment of clinically organ confined prostate cancer.
McLeod DG
Scand J Urol Nephrol Suppl; 1999; 203():35-9. PubMed ID: 10636568
[No Abstract] [Full Text] [Related]
11. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant hormone therapy with casodex in a dose 150 mg prior to radical prostatectomy in patients with prostatic cancer].
Rusakov IG; Petrov SB; Alekseev BIa; Veliev EI
Urologiia; 2004; (4):15-9. PubMed ID: 15457946
[No Abstract] [Full Text] [Related]
13. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
14. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
15. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
16. [Solitary peritoneal carcinomatosis in prostate cancer].
Brehmer B; Makris A; Wellmann A; Jakse G
Aktuelle Urol; 2007 Sep; 38(5):408-9. PubMed ID: 17907070
[TBL] [Abstract][Full Text] [Related]
17. Side-effects of treatments for locally advanced prostate cancer.
O'Connor KM; Fitzpatrick JM
BJU Int; 2006 Jan; 97(1):22-8. PubMed ID: 16336322
[No Abstract] [Full Text] [Related]
18. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]